Nasdaq
$0.4699▼ 1.24%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $6.9MShares out 14.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 1d agoAfter-hours26.10.24 05:30S-3Offering#●●●#●●●#●●●
Ensysce Biosciences, Inc.Bullish
Ensysce Biosciences has filed a registration statement for the resale of up to 433,907,000 shares of common stock, issuable upon the conversion of Series C Non-Voting Convertible Preferred Stock issued in connection with a merger and private placement transactions. The company will not receive any proceeds from the sale of these shares by the selling securityholders.…more
$0.4699-1.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.16Pre-market26.10.16 10:56filed8-K/AKey event
Ensysce Biosciences, Inc.
Ensysce Biosciences completed its acquisition of Cy Biopharma on August 5, 2026, and raised approximately $21.5 million through a private placement (PIPE). The merger expands the company's pipeline to include neuroplastogenic therapies alongside its existing pain management candidates. However, the company remains under scrutiny regarding Nasdaq listing compliance, and existing shareholders will face significant dilution from the merger and preferred stock conversion.…more
$0.4699-1.24%vs prev closeView filingShare - 9.29Pre-market26.09.29 21:318-KKey event
Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc. completed an amendment to its Series C Non-Voting Convertible Preferred Stock designation on September 25, 2026, by removing Section 6.5.3. This section previously granted holders the right to demand cash redemption if the company failed to deliver common shares upon conversion following stockholder approval.…more
$0.4699-1.24%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 8.31Pre-market26.08.31 21:35#●●●#●●●
Ensysce Biosciences Completes Enrollment for PF614-MPAR Clinical Study
Ensysce Biosciences has completed patient enrollment for the final stage of its PF614-MPAR clinical study, which tests an overdose-protection opioid technology. The drug features a proprietary safety mechanism designed to limit opioid release during excessive oral dosing.…more
$0.4699-1.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga